Gerard D Aversa, MD
Ophthalmology · Valley Stream, NYNPI 1548265523
Payments from drug & device makers
Across 429 payments — averaging $251.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$40K
- AbbVie$36K
- Kala Pharmaceuticals, Inc.$17K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- Glaukos Corporation$2K
- Alcon Research LLC$2K
- plus $8K from 19 others
What the payments were for
- Consulting fees$9,6759%
- Speaking & faculty fees$83,52577%
- Travel & lodging$3,2953%
- Food & beverage$11,23810%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 66 | $40,390 |
| AbbVie(2 entities) | 76 | $35,922 |
| Kala Pharmaceuticals, Inc. | 58 | $16,707 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $3,534 |
| Glaukos Corporation | 5 | $1,968 |
| Alcon Research LLC | 1 | $1,750 |
| Eyevance Pharmaceuticals LLC | 4 | $1,321 |
| Novartis | 48 | $1,315 |
| Johnson & Johnson Surgical Vision, Inc. | 9 | $840 |
| Ocular Therapeutix, Inc. | 14 | $773 |
| Alcon | 12 | $477 |
| Dompe US, Inc. | 11 | $473 |
| Oyster Point Pharma, Inc. | 22 | $410 |
| Tarsus Pharmaceuticals, Inc. | 28 | $361 |
| Mallinckrodt Hospital Products Inc. | 13 | $355 |
| Sun Pharmaceutical Industries Inc. | 16 | $334 |
| Aerie Pharmaceuticals, Inc. | 8 | $244 |
| Rxsight Inc | 3 | $182 |
| Sight Sciences, Inc. | 6 | $124 |
| Shire North American Group Inc | 5 | $103 |
| Harrow Eye, LLC | 4 | $98 |
| Biotissue Holdings Inc. | 3 | $67 |
| Amgen | 2 | $35 |
| Johnson & Johnson Vision Care, Inc. | 1 | $31 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$39,445
- MIEBO$39,200
- RESTASIS$14,758
- VUITY$14,333
- INVELTYS$10,383
- RESTASIS MULTIDOSE$6,050
- EYSUVIS$5,491
- LOTEMAX SM$3,318
- DEXTENZA$1,800
- AcrySof IQ VIVITY IOL$1,750
- Flarex$1,250
- CE-marked KXLA system$825
- Tecnis IOL$378
- Oxervate$231
- VERITAS Vision System$149
- enVista MX60 IOL$134
- RXSIGHT CONTACT LENS$132
- RXSIGHT INJECTOR CARTRIDGE$132
- RXSIGHT INJECTOR HANDPIECE$132
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$132
How this compares
$107,831 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 328 | $429,304 |
| OxervateCenegermin-Bkbj | 12 | $341,287 |
| XiidraLifitegrast | 135 | $189,984 |
| MieboPerfluorohexyloctane/Pf | 119 | $99,660 |
| ProlensaBromfenac Sodium | 230 | $77,841 |
| Cyclosporine | 100 | $63,221 |
| LumiganBimatoprost | 97 | $62,617 |
| InveltysLoteprednol Etabonate | 177 | $50,163 |
| XdemvyLotilaner | 16 | $28,905 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $19,502 |
| Prednisolone Acetate | 529 | $16,870 |
| Brimonidine Tartrate | 138 | $16,298 |
| Travoprost | 65 | $14,531 |
| TyrvayaVarenicline Tartrate | 19 | $12,370 |
| Alphagan PBrimonidine Tartrate | 23 | $10,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $35,922 | $521,768504 claims |
| Dompe US, Inc.Oxervate | $473 | $341,28712 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $40,390 | $289,644254 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax, Besivance | $3,534 | $96,286308 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $16,707 | $50,163177 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $361 | $28,90516 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $410 | $12,37019 claims |
| NovartisIlevro | $1,315 | $4,33712 claims |
| AlconSimbrinza | $477 | $3,47911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Valley Stream
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.